VRC

Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines

Retrieved on: 
Tuesday, May 17, 2022

In combining OVX836 with the NIAID candidates, we intend to unlock the synergy of pairing T- and B-cell activation to drastically improve influenza protection against future pandemic outbreaks.

Key Points: 
  • In combining OVX836 with the NIAID candidates, we intend to unlock the synergy of pairing T- and B-cell activation to drastically improve influenza protection against future pandemic outbreaks.
  • Osivax OVX836 is a nucleoprotein-targeting influenza vaccine developed using the companys proprietary oligoDOM technology.
  • Osivax is also exploring the broader application of its technology in both mRNA and subunit vaccines against a variety of indications.
  • NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.

Proactive news headlines including Cobalt Blue Holdings, Volt Resources, Solis Minerals and Paradigm Biopharmaceuticals

Retrieved on: 
Thursday, April 28, 2022

Click here

Key Points: 
  • Click here
    Solis Minerals Ltd (TSX-V:SLMN, ASX:SLM) has received results from the first two holes drilled at the Mostazal Copper Project in Chile, showing potential for a large copper system.
  • Click here
    Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has finalised its loyalty option offer to shareholders to raise A$23.6 million.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Proactive news headlines including Altech Chemicals, Dundas Minerals, Arovella Therapeutics and Sipa Resources

Retrieved on: 
Wednesday, April 20, 2022

Click here

Key Points: 
  • Click here
    KGL Resources Ltd (ASX:KGL) has appointed experienced mining leader Steven Rooney as chief operations officer, effective from 2 May 2022.
  • Click here
    AuKing Mining Ltd (ASX:AKN) is out to raise $7.1 million via a two-tranche placement and rights issue.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Proactive news headlines including Bardoc Gold, Emyria Ltd, Pantoro Ltd and Aeris Resources

Retrieved on: 
Wednesday, April 13, 2022

Click here

Key Points: 
  • Click here
    Aeris Resources Ltd (ASX:AIS) has reaffirmed its FY22 production guidance of between 18,500 and 19,500 tonnes of copper for the Tritton operations in NSW.
  • Click here
    Miramar Resources Ltd (ASX:M2R) is exploring the potential for multiple, large gold deposits at its 80%-owned Gidji joint venture project in WAs Eastern Goldfields.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Proactive news headlines including PVW Resources, Emperor Energy, GTI Resources and Meeka Gold

Retrieved on: 
Wednesday, April 6, 2022

Click here

Key Points: 
  • Click here
    GTI Resources Ltd (ASX:GTR) will pick up nearly 14,000 acres worth of contiguous ISR uranium exploration claims in Wyomings Great Divide Basin.
  • Click here
    Critical Resources Ltd (ASX:CRR) has secured approvals for a 5,000-metre diamond drilling program at the Mavis Lake Lithium Project in Ontario, Canada.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Value Research Center (VRC) authors Value Model integrating ESG and Sustainability Measures

Retrieved on: 
Wednesday, March 23, 2022

KYOTO, Japan, Mar 23, 2022 - (JCN Newswire) - The Value Research Center (VRC) launched an integrated Value Model of ESG and Sustainability measures in a new white paper issued today.

Key Points: 
  • KYOTO, Japan, Mar 23, 2022 - (JCN Newswire) - The Value Research Center (VRC) launched an integrated Value Model of ESG and Sustainability measures in a new white paper issued today.
  • A Value Model for Responsible Business: The new Value Research Center (VRC) white paper was officially released today.
  • The VRC's new white paper entitled "A Value Model for Responsible Business", integrates an additional 346 impact measurements from 6 new frameworks into the initial model.
  • The white paper is available for download at the VRC website:
    The Value Research Center (VRC) was officially established at Doshisha University in Kyoto, Japan in November 2021.

Proactive news headlines including Australian Potash, Chimeric Therapeutics, Chalice Mining and Australian Gold and Copper

Retrieved on: 
Wednesday, March 2, 2022

Click here

Key Points: 
  • Click here
    Chimeric Therapeutics Ltd (ASX:CHM) has opened the retail component of its rights offer, after raising about $7.37 million from the institutional component.
  • Click here
    Australian Gold and Copper Ltd (ASX:AGC) has hit near-surface gold along the 15-kilometre Boxdale-Carlisle Reefs gold trend in central New South Wales.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

M&A Science Hosts Virtual Summit

Retrieved on: 
Thursday, February 17, 2022

At the end of the summit, CEO and Founder of M&A Science, Kison Patel, will host a happy hour and introduce M&A Science's new consulting services and partnership opportunities.

Key Points: 
  • At the end of the summit, CEO and Founder of M&A Science, Kison Patel, will host a happy hour and introduce M&A Science's new consulting services and partnership opportunities.
  • Also, the M&A Science consulting services shift teams away from traditional approaches to M&A in which culture is overshadowed by finances.
  • Originally a podcast series, M&A Science has evolved into a diverse community of M&A professionals looking to evolve the industry.
  • Today, along with the M&A Science podcast, its portfolio offerings include the M&A Science Academy, the Agile M&A framework, consulting services, and a job board.

AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19

Retrieved on: 
Friday, February 11, 2022

Source: AbCellera

Key Points: 
  • Source: AbCellera
    At the start of the COVID-19 pandemic we and our partners prioritized speed in getting therapies out to patients.
  • This resulted in the discovery of bamlanivimab, the first COVID-19 antibody to reach the clinic and receive FDA Emergency Use Authorization, said Carl Hansen, Ph.D., CEO of AbCellera.
  • We then shifted our efforts to discovering a next-generation antibody therapeutic, this time prioritizing maximum potency and breadth of neutralization.
  • It is being studied for the treatment of mild to moderate COVID-19 both as a monotherapy and together with other antibodies.

Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments

Retrieved on: 
Friday, February 11, 2022

The U.S. government will accept the doses of bebtelovimab if it is granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • The U.S. government will accept the doses of bebtelovimab if it is granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).
  • Pseudovirus and authentic virus testing demonstrate that bebtelovimab retains full neutralizing activity against Omicron currently the predominant variant in the U.S.
  • In addition, pseudovirus testing with bebtelovimab demonstrates that it retains neutralization against all other known variants of interest and concern, including BA.2.
  • Pseudovirus and authentic virus testing confirmed bebtelovimab maintains binding and neutralizing activity across currently known and reported variants of concern.